BrainsWay

Company Overview

BrainsWay is headquartered in Jerusalem, Israel and was founded in 2003, which means the company has been building medical devices for 23 years. The company operates in US + international and is publicly traded under ticker BWAY. Annual revenue is approximately $40M (2024). Israeli company that developed Deep TMS using patented H-coil technology. FDA-cleared for depression, OCD, and smoking cessation. Differentiator is deeper brain stimulation (6cm vs 2cm for standard TMS). Growing in the US psychiatry market.

The company's product portfolio centers on Deep TMS (H-Coil Technology), with platforms targeting 1 device category: tms neuromodulation. Portfolio breadth matters for buyers because manufacturers with multiple platforms can bundle training, service contracts, and consumable agreements across devices. Single-category manufacturers typically have less negotiating flexibility, though they can offer deeper expertise in their specific domain. When evaluating BrainsWay, the right question is not whether the portfolio is wide or narrow, but whether the specific platform you need is strategically important to the company or a legacy product being phased out.

Manufacturer financial stability is a real consideration for capital equipment buyers. BrainsWay's public market visibility means quarterly financials, analyst coverage, and SEC-filed risk factors are all accessible. For physicians considering a BrainsWay platform, the questions worth asking are warranty term length, parts availability commitments, software update policy, and service response times in your specific region. Manufacturers in financial distress sometimes cut these obligations first, and they rarely announce it publicly. The strongest signal of real manufacturer health is whether they are investing in new product development, acquiring complementary technology, or simply coasting on existing revenue.

Technology Platform

BrainsWay's core technology stack includes Deep TMS (H-Coil Technology). Each platform represents distinct R&D investment and targets specific clinical indications. Physicians evaluating BrainsWay devices should understand which technology drives which platform because the mechanism of action varies across the company's product lineup.

The technology portfolio is deeper than a single-platform manufacturer, which matters for practices that want to consolidate device purchases with one vendor for training, service, and consumable efficiency. Platform breadth also signals R&D commitment, though it can stretch engineering and support resources thin when the company expands into too many categories at once.

• Deep TMS (H-Coil Technology)

Product Lineup

BrainsWay currently produces the devices listed below across 1 category. Each device links to a full independent review with pricing, clinical evidence, pros and cons, and comparisons against category alternatives.

Market Position

BrainsWay competes across 1 device category, which positions the company differently in each market segment. In some categories, BrainsWay leads on installed base and brand recognition. In others, the company is the value alternative or the technology challenger. Buyers should evaluate the company category by category rather than treating it as uniformly strong or weak across its entire portfolio.

The competitive set varies by category. In tms neuromodulation, BrainsWay faces a different competitive landscape than in any other segment. Some categories are dominated by 2-3 incumbents. Others are fragmenting as new entrants push on price or differentiate on clinical evidence. For physicians evaluating BrainsWay platforms, the right question is not whether the company is good or bad in general, but how well its specific platform stacks up against the named competitors in your category of interest.

Strengths and Weaknesses

BrainsWay's strengths typically include manufacturer scale ($40M (2024) in annual revenue), international presence (US + international), and a publicly traded structure. Companies with this profile usually have stronger sales infrastructure, better training programs, and more predictable parts and service support than smaller competitors. The technology portfolio (Deep TMS (H-Coil Technology)) represents real R&D investment that smaller players can't match.

Weaknesses to weigh: any large manufacturer faces pricing pressure from value-tier competitors, distribution challenges in regions where dealer networks are thin, and the constant risk that a clinical safety signal in one product affects perception of the entire portfolio. Physicians evaluating BrainsWay should look at the specific platform they're considering rather than the parent brand. A strong manufacturer can have weak platforms in specific categories, and a struggling manufacturer can have category-leading products. Brand-level reputation is a starting point, not a substitute for platform-level diligence.

Who Should Consider BrainsWay

BrainsWay fits best for practices that value public market visibility and analyst-tracked financials, want access to platforms across 1 category, and benefit from international support infrastructure. Practices that prioritize bundled training, multi-device service contracts, or trade-in programs across a manufacturer's portfolio also benefit from larger players like BrainsWay.

The fit is weaker for practices that prioritize the absolute lowest price, want to work with smaller manufacturers that offer more personalized service, or need niche features that only specialist competitors provide. The right manufacturer depends on what your practice values more than the manufacturer itself. Match the company to your priorities, not the other way around.

Risk Factors for Buyers

Every medical device purchase carries manufacturer risk. BrainsWay's risk profile reflects its size ($40M (2024)), history (23 years of operation), and structure (public ownership). Public-company transparency helps in one direction: you can read the quarterly risk factors section in their 10-K and see what management itself considers the biggest threats to the business. Quarterly earnings calls reveal whether the company is meeting analyst expectations, losing market share, or facing margin compression from competitors. Stock price movement is a noisy but useful sentiment indicator.

Specific risks to monitor before signing a purchase contract with BrainsWay: warranty coverage (duration, what is covered, and exclusions), parts and service response times in your region (not the national average), software update policy (are updates included in the maintenance contract or charged separately?), consumable pricing stability (have consumable prices increased by more than 5% annually over the past three years?), and ownership change risk (is the company rumored to be for sale, spinning off a division, or preparing for an IPO or acquisition?). Each of these questions has a real answer that a well-informed buyer can verify through conversations with existing BrainsWay customers in your region.

What to Negotiate with BrainsWay

Capital equipment sales reps have significant pricing flexibility that practice buyers rarely fully capture. The published list price on a BrainsWay platform is almost never the real transaction price. Most deals close at 10-20% below list for single-device purchases and 20-30% below list for multi-device bundles. End-of-quarter and end-of-year timing gives you a real pricing advantage because reps have quota pressure to close before their fiscal period closes. Trade-in programs for older devices can reduce net cost by another 10-20%, though the trade-in valuation is often where manufacturers claw back the discount.

Beyond price, the items worth negotiating with BrainsWay include: extended warranty coverage (ask for 24-36 months instead of the standard 12), applicator or accessory inclusions (always ask for additional applicators, treatment tips, or probes thrown in at no cost), consumable starter packages (enough consumables to cover 60-90 days of typical practice use), training and certification (ensure multiple providers in your practice can be trained without additional fees), marketing support (co-marketing funds, patient education materials, or launch campaign support), and trade-in credit for any existing devices you are replacing. A well-negotiated bundle can reduce effective capital cost by 25-35% versus the initial quote. The mistake most physicians make is accepting the first deck without pushing back on any of these items.